Biosig Technologies (OTCMKTS:BSGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $1.50 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 5.01% from the company’s previous close.
According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “
Separately, Chardan Capital restated a “buy” rating on shares of Biosig Technologies in a research report on Sunday, October 1st.
COPYRIGHT VIOLATION WARNING: “Biosig Technologies (BSGM) Rating Increased to Buy at Zacks Investment Research” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/01/biosig-technologies-bsgm-rating-increased-to-buy-at-zacks-investment-research.html.
Biosig Technologies Company Profile
BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biosig Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.